This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that
will include an 8-day treatment period followed by a 1-week follow-up period in patients
experiencing symptoms of an acute exacerbation of gouty arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.